ArticleProblemy endokrinologii2024
KI-67 as a predictive indicator of papillary thyroid cancer in Iraqi patients.
Article in Problemy endokrinologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Association of Interstitial Fibrosis and Ki67 Marker Expression in Papillary Thyroid Carcinoma with Histopathological Findings and Prognosis of Total Thyroidectomy.Journal of clinical medicine · 2026Article
- The diagnostic efficacy of serum galectin-3 and other markers in papillary thyroid carcinoma.Gland surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKI-67 (MKI-67 in humans) is a protein able to bind to DNA which contributes to cell growth and cell proliferation. KI-67 is currently considered as a biomarker that is widely utilized as prognostic indicator for evaluating cell proliferation, diagnosing diseases, and conducting research. Several different kinds of cancer have high Ki-67 expression, which simplifying the choice of treatment for individuals with various cancer types.
aimThe objective was to evaluate the expression of KI67 in patients suffering papillary thyroid cancer (PTC) also the association between patients age and gender and KI67 expression. MATERIALS AND
methodsTo undertake an in-depth investigation of KI67 in malignant and normal tissues, we used thyroid tissue sections to analyze KI67 expression in 70 samples, 50 different PTC (44 female and 6 male), and 20 normal types (10 for each gender). Each group's average age is between 20 and 60.
resultsThe analysis of the data revealed a substantial difference in the expression of ki67 between the patients and control groups. Ki67 expression and either gender or age did not significantly correlate.
conclusionThis study suggest that KI67 may be a crucial marker for assessing the aggressiveness of tumors and inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.